Amryt buys Aegerion via bankruptcy, adding sales to support R&D - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Amryt buys Aegerion via bankruptcy, adding sales to support R&D

Home
2019
Amryt buys Aegerion via bankruptcy, adding sales to support R&D

Recent News

Open Orphan signs €4.4m contract with global company
Open Orphan wins €4m contract to conduct trial for new RSV treatment
Open Orphan deal to generate ‘significant revenue’ for Venn Life Sciences
Open Orphan signs deal to carry out Covid-19 vaccine trial
Open Orphan agrees contract for Covid-19 vaccine trial
Open Orphan wins contact for Covid-19 vaccine trial

Amryt buys Aegerion via bankruptcy, adding sales to support R&D

25th September 2019

https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&newsid=1218097

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2020 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences